Rapid Micro Biosystems (RPID) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RPID Stock Forecast

Rapid Micro Biosystems stock forecast is as follows: an average price target of $8.00 (represents a 396.89% upside from RPID’s last price of $1.61) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.

RPID Price Target

The average price target for Rapid Micro Biosystems (RPID) is $8.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 396.89% upside from RPID's last price of $1.61.

RPID Analyst Ratings

Hold

According to 1 Wall Street analysts, Rapid Micro Biosystems's rating consensus is 'Hold'. The analyst rating breakdown for RPID stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Rapid Micro Biosystems Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 11, 2022		Morgan Stanley	$8.00	$4.11	94.65%	396.89%

The latest Rapid Micro Biosystems stock forecast, released on May 11, 2022 by Morgan Stanley company, set a price target of $8.00, which represents a 94.65% increase from the stock price at the time of the forecast ($4.11), and a 396.89% increase from RPID last price ($1.61).

Rapid Micro Biosystems Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.61	$1.61	$1.61
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Rapid Micro Biosystems stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rapid Micro Biosystems's last price of $1.61. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 11, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold

Rapid Micro Biosystems's last stock rating was published by Morgan Stanley on May 11, 2022. The company gave RPID a "Equal-Weight" rating, the same as its previous rate.

Rapid Micro Biosystems Financial Forecast

Rapid Micro Biosystems Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	-	-	-	-	$6.34M	$6.14M	$5.00M	$5.04M	$4.37M	$4.74M	$3.86M	$4.16M	$5.21M	$6.90M	$6.13M
Avg Forecast	$9.20M	$8.10M	$7.40M	$6.70M	$7.60M	$6.55M	$6.00M	$5.50M	$6.15M	$5.55M	$4.15M	$4.13M	$4.50M	$3.97M	$4.35M	$5.16M	$5.87M	$6.57M	$5.93M
High Forecast	$9.20M	$8.10M	$7.40M	$6.70M	$7.60M	$6.55M	$6.00M	$5.50M	$6.23M	$5.55M	$4.15M	$4.13M	$4.66M	$3.97M	$4.35M	$5.16M	$5.87M	$6.57M	$5.93M
Low Forecast	$9.20M	$8.10M	$7.40M	$6.70M	$7.60M	$6.55M	$6.00M	$5.50M	$6.07M	$5.55M	$4.15M	$4.13M	$4.34M	$3.97M	$4.35M	$5.16M	$5.87M	$6.57M	$5.93M
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	1.03%	1.11%	1.21%	1.22%	0.97%	1.19%	0.89%	0.81%	0.89%	1.05%	1.03%

Rapid Micro Biosystems's average Quarter revenue forecast for Mar 24 based on 1 analysts is $5.50M, with a low forecast of $5.50M, and a high forecast of $5.50M. RPID's average Quarter revenue forecast represents a -13.21% decrease compared to the company's last Quarter revenue of $6.34M (Dec 23).

Rapid Micro Biosystems EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	$-12.48M	$-14.45M	$-15.05M	$-14.87M	$-17.26M	$-16.15M	$-13.69M	$-14.34M	$-14.14M	$-25.36M	$-10.54M
Avg Forecast	$-9.20M	$-8.10M	$-7.40M	$-6.70M	$-7.60M	$-6.55M	$-6.00M	$-5.50M	$-6.15M	$-5.55M	$-4.15M	$-4.13M	$-4.50M	$-3.97M	$-4.35M	$-13.47M	$-5.87M	$-6.57M	$-443.86M
High Forecast	$-9.20M	$-8.10M	$-7.40M	$-6.70M	$-7.60M	$-6.55M	$-6.00M	$-5.50M	$-6.07M	$-5.55M	$-4.15M	$-4.13M	$-4.34M	$-3.97M	$-4.35M	$-10.77M	$-5.87M	$-6.57M	$-355.09M
Low Forecast	$-9.20M	$-8.10M	$-7.40M	$-6.70M	$-7.60M	$-6.55M	$-6.00M	$-5.50M	$-6.23M	$-5.55M	$-4.15M	$-4.13M	$-4.66M	$-3.97M	$-4.35M	$-16.16M	$-5.87M	$-6.57M	$-532.64M
Surprise %	-	-	-	-	-	-	-	-	2.03%	2.60%	3.63%	3.60%	3.84%	4.07%	3.15%	1.06%	2.41%	3.86%	0.02%

undefined analysts predict RPID's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Rapid Micro Biosystems's previous annual EBITDA (undefined) of $NaN.

Rapid Micro Biosystems Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	$-11.17M	$-13.39M	$-14.02M	$-13.89M	$-16.45M	$-16.34M	$-13.09M	$-14.93M	$-14.61M	$-24.99M	$-11.83M
Avg Forecast	$-10.04M	$-9.61M	$-9.17M	$-9.17M	$-9.83M	$-11.14M	$-12.08M	$-12.66M	$-13.10M	$-13.39M	$-14.85M	$-15.94M	$-15.72M	$-15.99M	$-13.85M	$-14.03M	$-12.21M	$-16.90M	$-498.37M
High Forecast	$-10.04M	$-9.61M	$-9.17M	$-9.17M	$-9.83M	$-11.14M	$-12.08M	$-12.66M	$-12.68M	$-13.39M	$-14.85M	$-15.94M	$-15.01M	$-15.99M	$-13.85M	$-11.22M	$-12.21M	$-16.90M	$-398.70M
Low Forecast	$-10.04M	$-9.61M	$-9.17M	$-9.17M	$-9.83M	$-11.14M	$-12.08M	$-12.66M	$-13.10M	$-13.39M	$-14.85M	$-15.94M	$-16.44M	$-15.99M	$-13.85M	$-16.83M	$-12.21M	$-16.90M	$-598.05M
Surprise %	-	-	-	-	-	-	-	-	0.85%	1.00%	0.94%	0.87%	1.05%	1.02%	0.95%	1.06%	1.20%	1.48%	0.02%

Rapid Micro Biosystems's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RPID's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Rapid Micro Biosystems SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	$8.70M	$9.70M	$9.93M	$9.93M	$11.26M	$11.12M	$9.89M	$9.55M	$9.12M	$8.37M	$6.75M
Avg Forecast	$13.24M	$11.66M	$10.65M	$9.64M	$10.94M	$9.43M	$8.63M	$7.91M	$8.85M	$7.99M	$5.97M	$5.95M	$6.48M	$5.71M	$6.26M	$7.43M	$8.44M	$9.45M	$8.54M
High Forecast	$13.24M	$11.66M	$10.65M	$9.64M	$10.94M	$9.43M	$8.63M	$7.91M	$8.97M	$7.99M	$5.97M	$5.95M	$6.70M	$5.71M	$6.26M	$7.43M	$8.44M	$9.45M	$8.54M
Low Forecast	$13.24M	$11.66M	$10.65M	$9.64M	$10.94M	$9.43M	$8.63M	$7.91M	$8.73M	$7.99M	$5.97M	$5.95M	$6.25M	$5.71M	$6.26M	$7.43M	$8.44M	$9.45M	$8.54M
Surprise %	-	-	-	-	-	-	-	-	0.98%	1.21%	1.66%	1.67%	1.74%	1.95%	1.58%	1.29%	1.08%	0.89%	0.79%

Rapid Micro Biosystems's average Quarter SG&A projection for Mar 24 is $7.91M, based on 1 Wall Street analysts, with a range of $7.91M to $7.91M. The forecast indicates a -9.01% fall compared to RPID last annual SG&A of $8.70M (Dec 23).

Rapid Micro Biosystems EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	$-0.00	$-0.31	$-0.33	$-0.32	$-0.39	$-0.38	$-0.31	$-0.35	$-0.35	$-0.71	$-0.31
Avg Forecast	$-0.23	$-0.22	$-0.21	$-0.21	$-0.23	$-0.26	$-0.28	$-0.29	$-0.30	$-0.31	$-0.34	$-0.36	$-0.36	$-0.37	$-0.32	$-0.34	$-0.28	$-0.39	$-1.09
High Forecast	$-0.23	$-0.22	$-0.21	$-0.21	$-0.23	$-0.26	$-0.28	$-0.29	$-0.29	$-0.31	$-0.34	$-0.36	$-0.34	$-0.37	$-0.32	$-0.34	$-0.28	$-0.39	$-1.09
Low Forecast	$-0.23	$-0.22	$-0.21	$-0.21	$-0.23	$-0.26	$-0.28	$-0.29	$-0.30	$-0.31	$-0.34	$-0.36	$-0.38	$-0.37	$-0.32	$-0.34	$-0.28	$-0.39	$-1.09
Surprise %	-	-	-	-	-	-	-	-	0.00%	1.01%	0.97%	0.88%	1.08%	1.04%	0.98%	1.04%	1.25%	1.83%	0.28%

According to undefined Wall Street analysts, Rapid Micro Biosystems's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RPID previous annual EPS of $NaN (undefined).

Rapid Micro Biosystems Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
OWLT	Owlet	$4.51	$196.00	4245.90%	Buy
RPID	Rapid Micro Biosystems	$1.61	$8.00	396.89%	Hold
BJDX	Bluejay Diagnostics	$4.11	$10.00	143.31%	Buy
LUNG	Pulmonx	$5.83	$13.00	122.98%	Buy
RXST	RxSight	$31.58	$70.14	122.10%	Buy
KIDS	OrthoPediatrics	$24.84	$39.50	59.02%	Buy
TMCI	Treace Medical Concepts	$10.42	$14.50	39.16%	Buy
LIVN	LivaNova	$50.73	$67.00	32.07%	Buy
OFIX	Orthofix Medical	$18.71	$24.00	28.27%
BVS	Bioventus	$10.49	$12.00	14.39%	Buy
SRDX	Surmodics	$35.78	$39.50	10.40%	Buy

RPID Forecast FAQ

Is Rapid Micro Biosystems a good buy?

No, according to 1 Wall Street analysts, Rapid Micro Biosystems (RPID) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of RPID's total ratings.

What is RPID's price target?

Rapid Micro Biosystems (RPID) average price target is $8 with a range of $8 to $8, implying a 396.89% from its last price of $1.61. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Rapid Micro Biosystems stock go up soon?

According to Wall Street analysts' prediction for RPID stock, the company can go up by 396.89% (from the last price of $1.61 to the average price target of $8), up by 396.89% based on the highest stock price target, and up by 396.89% based on the lowest stock price target.

Can Rapid Micro Biosystems stock reach $2?

RPID's average twelve months analyst stock price target of $8 supports the claim that Rapid Micro Biosystems can reach $2 in the near future.

What are Rapid Micro Biosystems's analysts' financial forecasts?

Rapid Micro Biosystems's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $25.65M (high $25.65M, low $25.65M), average EBITDA is $-25.65M (high $-25.65M, low $-25.65M), average net income is $-45.707M (high $-45.707M, low $-45.707M), average SG&A $36.91M (high $36.91M, low $36.91M), and average EPS is $-1.047 (high $-1.047, low $-1.047). RPID's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $31.4M (high $31.4M, low $31.4M), average EBITDA is $-31.4M (high $-31.4M, low $-31.4M), average net income is $-37.992M (high $-37.992M, low $-37.992M), average SG&A $45.19M (high $45.19M, low $45.19M), and average EPS is $-0.87 (high $-0.87, low $-0.87).

Did the RPID's actual financial results beat the analysts' financial forecasts?

Based on Rapid Micro Biosystems's last annual report (Dec 2023), the company's revenue was $22.52M, beating the average analysts forecast of $19.98M by 12.69%. Apple's EBITDA was $-56.563M, beating the average prediction of $-19.983M by 183.05%. The company's net income was $-52.467M, missing the average estimation of $-57.279M by -8.40%. Apple's SG&A was $38.26M, beating the average forecast of $28.76M by 33.04%. Lastly, the company's EPS was $-0.0012, missing the average prediction of $-1.312 by -99.91%. In terms of the last quarterly report (Dec 2023), Rapid Micro Biosystems's revenue was $6.34M, beating the average analysts' forecast of $6.15M by 3.04%. The company's EBITDA was $-12.483M, beating the average prediction of $-6.15M by 102.98%. Rapid Micro Biosystems's net income was $-11.172M, missing the average estimation of $-13.101M by -14.72%. The company's SG&A was $8.7M, missing the average forecast of $8.85M by -1.72%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.3 by -99.90%